Lixisenatide, another short-acting GLP-1RA, did not provide evidence of CV RR in the ELIXA (The Evaluation of Lixisenatide in Acute Coronary Syndrome) trial (4)
While human data remains limited, this area is attracting significant research attention particularly relevant in clinical settings where patients use multiple pharmaceuticals that carry hepatotoxic risk
The technique requires longer needles than subcutaneous injections and carries slightly higher discomfort potential
Lee M, Lauren BN, Zhan T, Choi J, Klebanoff M, Abu Dayyeh B, et al
Though not FDA-approved for weight loss, it's used off-label to target stubborn fat areas
At the same time, it fine-tunes which collagen-clearing enzymes are active, striking a balance between breaking down old tissue and building new tissue, while also calming inflammation